Abstract
Transient modulation of E-cadherin-mediated cell-cell adhesion may improve paracellular drug delivery through biological barriers. Therefore, there is a need to develop an efficient method to evaluate cadherin peptides that can modulate the intercellular junctions. The objective of this study was to establish a novel assay to evaluate peptide activity in modulating E-cadherin-mediated homophilic interactions, based on the homotypic adhesion of Caco-2 cells. Fluorescence-labeled Caco-2 single cells were incubated with Caco-2 monolayers that were treated beforehand with Ca2+-free medium. The homotypic adhesion in the presence or absence of peptide and antibody was determined fluorometrically. The Ca2+-deficient pretreatment dramatically increased the number of single cells bound to the monolayers. Immunofluorescence staining showed that some of E-cadherins became accessible without surfactant-induced permeabilization of Caco-2 cell monolayers after the Ca2+-deficient pretreatment. The homotypic adhesion was largely dependent on extracellular Ca2+ concentrations and significantly inhibited by the presence of anti-E-cadherin monoclonal antibody DECMA-1. In contrast, DECMA-1 did not inhibit E-cadherin-independent adhesion, such as the homotypic adhesion of Caco-2 cells in the absence of Ca2+ or the heterotypic adhesion of Molt-3 T cells to Caco-2 monolayers. These results indicate the predominant involvement of E-cadherin-mediated cell-cell adhesion in this assay. E-cadherin-derived peptides, which had been shown in our previous studies to inhibit E-cadherin-mediated cell-cell adhesion, significantly inhibited homotypic adhesion in a dose-dependent manner. These results, taken together, suggest that the present assay can be used for evaluation of peptide, protein, or antibody activity in modulating the E-cadherin-mediated homophilic interactions in the context of whole live cells.
Footnotes
-
This work was supported by postdoctoral fellowship from American Heart Association (Heartland Affiliate) and Grant R01 EB-00226 from the National Institutes of Health.
-
doi:10.1124/jpet.105.097535.
-
ABBREVIATIONS: HAV, His-Ala-Val; BBMEC, bovine brain microvessel endothelial cell; MDCK, Madin-Darby canine kidney; TEER, transepithelial electrical resistance; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; mAb, monoclonal antibody; FITC, fluorescein isothiocyanate; HBSS, Hanks' balanced salt solution; PBS, phosphate-buffered saline; RT, room temperature; EBSS, Earle's balanced salt solution; BSA, bovine serum albumin; BCECF, 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein; AM, acetoxymethyl ester; CHES, 2-(cyclohexylamino)ethanesulfonic acid.
- Received October 21, 2005.
- Accepted December 20, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|